We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+4.44%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$459M
AUM Growth
-$44.7M
Cap. Flow
-$55.5M
Cap. Flow %
-12.09%
Top 10 Hldgs %
60.52%
Holding
51
New
14
Increased
5
Reduced
22
Closed
10

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$45.3M
2
SNY icon
Sanofi
SNY
+$45.2M
3
ABT icon
Abbott
ABT
+$31M
4
BIIB icon
Biogen
BIIB
+$26.8M
5
CNC icon
Centene
CNC
+$10.9M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$83.5M
2
AGN
Allergan plc
AGN
+$38.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$29.9M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
TVTX icon
Travere Therapeutics
TVTX
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
2 Financials 4.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
26
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.61M 1.22%
144,624
-238,300
-62% -$8.56M
KTWO
27
DELISTED
K2M Group Holdings, Inc
KTWO
$5.53M 1.2%
+356,300
New +$5.03M
TNDM icon
28
Tandem Diabetes Care
TNDM
$1.17B
$4.64M 1.01%
61,531
-27,414
-31% -$2.21M
ELOS
29
DELISTED
Syneron Medical Ltd
ELOS
$3.92M 0.85%
510,240
-757,742
-60% -$5.4M
FOMX
30
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.8M 0.83%
598,397
-1,000,634
-63% -$6.64M
BHC icon
31
Bausch Health
BHC
$1.8B
$3.33M 0.73%
+165,400
New +$4.68M
RCKT icon
32
Rocket Pharmaceuticals
RCKT
$376M
$3.31M 0.72%
111,256
-75,719
-40% -$2.66M
RIGL icon
33
Rigel Pharmaceuticals
RIGL
$750M
$3.22M 0.7%
144,300
-17,320
-11% -$431K
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.2M 0.7%
187,219
-20,390
-10% -$365K
NDRM
35
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.18M 0.69%
195,800
-19,600
-9% -$330K
VXRT
36
DELISTED
Vaxart
VXRT
$2.85M 0.62%
184,961
-510
-0.3% -$8.48K
ELDN icon
37
Eledon Pharmaceuticals
ELDN
$314M
$2.82M 0.61%
3,154
-779
-20% -$859K
AGRX
38
DELISTED
Agile Therapeutics
AGRX
$2.75M 0.6%
181
-25
-12% -$342K
ESPR
39
DELISTED
Esperion Therapeutics
ESPR
$2.17M 0.47%
+219,743
New +$3.64M
PRTK
40
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.87M 0.41%
+134,219
New +$1.98M
ZGNX
41
DELISTED
Zogenix, Inc.
ZGNX
$1.73M 0.38%
214,900
-53,700
-20% -$524K
ANIP icon
42
ANI Pharmaceuticals
ANIP
$1.8B
– –
-223,871
Closed -$7.54M
SEM
43
DELISTED
Select Medical
SEM
– –
-1,200,134
Closed -$7.64M
TEVA icon
44
Teva Pharmaceuticals
TEVA
$37.3B
– –
-558,889
Closed -$29.9M
NVRO
45
DELISTED
NEVRO CORP.
NVRO
– –
-1,483,730
Closed -$83.5M
SIEN
46
DELISTED
Sientra, Inc.
SIEN
– –
-31,407
Closed -$2.15M
KDNY
47
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-42,736
Closed -$2.74M
LCI
48
DELISTED
Lannett Company, Inc.
LCI
– –
-67,900
Closed -$4.87M
AGN
49
DELISTED
Allergan plc
AGN
– –
-143,748
Closed -$38.5M
DERM
50
DELISTED
Dermira, Inc.
DERM
– –
-263,300
Closed -$5.45M
1
2
3

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Senzar Asset Management held 51 positions worth $459M, down 8.9% from $504M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Senzar Asset Management withdrew a net $55.5M in Q2 2016, closing 10 positions and reducing 22 holdings. Its most notable exit was NEVRO CORP., an estimated $83.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials.

Against the trend, Senzar Asset Management opened a new position in Eli Lilly worth $47.4M.

  • Senzar Asset Management's largest Q2 2016 buy was Eli Lilly: 601,800 shares worth $47.4M.
  • Senzar Asset Management added most to Shire pic in Q2 2016, an estimated $7.67M increase.
  • Senzar Asset Management's biggest Q2 2016 reduction was Amgen, cutting an estimated $17.6M.
  • Senzar Asset Management fully exited NEVRO CORP. in Q2 2016, selling an estimated $83.5M.
  • Senzar Asset Management's ten largest holdings make up 61% of its $459M portfolio in Q2 2016.
  • Senzar Asset Management opened 14 new positions and closed 10 in Q2 2016.
  • Senzar Asset Management's portfolio value fell 8.9% quarter-over-quarter to $459M.

Based on Senzar Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.